Cleared Special

K033915 - MODIFICATION TO SERAQUEST EB VCA IGG

K033915 is the FDA 510(k) clearance for MODIFICATION TO SERAQUEST EB VCA IGG by Quest Intl., Inc.. It is a Class 1 Microbiology device (product code LSE) cleared through the Special 510(k) pathway after a 29-day FDA review.

K033915 · Quest Intl., Inc. · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jan 2004
Decision
29d
Days
Class 1
Risk

K033915 is an FDA 510(k) clearance for the MODIFICATION TO SERAQUEST EB VCA IGG. Classified as Epstein-barr Virus, Other (product code LSE), Class I - General Controls.

Submitted by Quest Intl., Inc. (North Miami, US). The FDA issued a Cleared decision on January 16, 2004 after a review of 29 days - a notably fast clearance cycle.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3235 - the FDA microbiology device framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

View all Quest Intl., Inc. devices

Submission Details

510(k) Number K033915 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 18, 2003
Decision Date January 16, 2004
Days to Decision 29 days
Submission Type Special
Review Panel Microbiology (MI)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
73d faster than avg
Panel avg: 102d · This submission: 29d
Pathway characteristics
Modification to existing cleared device.

Device Classification

Product Code LSE Epstein-barr Virus, Other
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 866.3235
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.

Regulatory Peers - LSE Epstein-barr Virus, Other

All 24
Devices cleared under the same product code (LSE) and FDA review panel - the closest regulatory comparables to K033915.
BIOPLEX 2200 EBV IGG PANEL FOR BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM
K062211 · Bio-Rad Laboratories, Inc. · Dec 2006
BIOPLEX 2200 EBV IGM PANEL ON BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM
K062213 · Bio-Rad Laboratories, Inc. · Dec 2006
LIAISON EA IGG
K060204 · DiaSorin, Inc. · Oct 2006
ETI-EA-G ASSAY
K992191 · DiaSorin, Inc. · Jul 1999
COPALIS MULTIPLEX EBV ANTIBODY ASSAY
K991660 · DiaSorin, Inc. · Jun 1999
EBV-VCA IGG ELISA TEST SYSTEM
K981812 · Diamedix Corp. · Mar 1999